These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 10155094)
21. Readministration of abciximab in percutaneous coronary intervention. Fry ET J Invasive Cardiol; 1999 Apr; 11(4):251-8. PubMed ID: 10745525 [TBL] [Abstract][Full Text] [Related]
22. [Theombolysis with GP IIb/IIIa-receptor blockader. Platelt aggregation inhibition: clear indications, new strategies]. Internist (Berl); 1998 Dec; 39(12 Suppl Plattchena):1-4. PubMed ID: 10101692 [No Abstract] [Full Text] [Related]
23. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials. van de Werf F Eur Heart J; 1996 Mar; 17(3):325-6. PubMed ID: 8737200 [No Abstract] [Full Text] [Related]
24. Future trials of antiplatelet agents in cardiac ischemia. Throckmorton DC N Engl J Med; 2001 Jun; 344(25):1937-9. PubMed ID: 11419432 [No Abstract] [Full Text] [Related]
26. Routine use of abciximab in coronary stenting? Stables RH Lancet; 1998 Jul; 352(9122):81-2. PubMed ID: 9672267 [No Abstract] [Full Text] [Related]
27. The safety and efficacy of glycoprotein IIb/IIIa inhibitors for primary angioplasty: more options to choose and more time to decide. Moliterno DJ; Ziada KM J Am Coll Cardiol; 2008 Feb; 51(5):536-7. PubMed ID: 18237681 [No Abstract] [Full Text] [Related]
28. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty. Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045 [TBL] [Abstract][Full Text] [Related]
29. Provisional use of glycoprotein IIb/IIIa inhibitors in the era of dual antiplatelet therapy--do "bailouts" pay off? Jeremias A; Gruberg L J Invasive Cardiol; 2009 Jun; 21(6):264-5. PubMed ID: 19494401 [No Abstract] [Full Text] [Related]
30. Antiplatelet therapy for ischemic heart disease. Lange RA; Hillis LD N Engl J Med; 2004 Jan; 350(3):277-80. PubMed ID: 14724308 [No Abstract] [Full Text] [Related]
31. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466 [TBL] [Abstract][Full Text] [Related]
36. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A; N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302 [TBL] [Abstract][Full Text] [Related]
37. Reversal of recurrent thrombocytopenia due to abciximab. Sharma V; Mascarenhas D J Invasive Cardiol; 2004 Sep; 16(9):537-8. PubMed ID: 15353816 [No Abstract] [Full Text] [Related]
38. Delayed immune-mediated thrombocytopenia after re-exposure to abciximab therapy. Rasti M; Blostein M Can J Cardiol; 2011; 27(6):869.e13-4. PubMed ID: 21885241 [TBL] [Abstract][Full Text] [Related]
39. Interventional therapy for coronary artery disease. Shah PB; Lilly CM Am J Respir Crit Care Med; 2002 Sep; 166(6):791-6. PubMed ID: 12231486 [No Abstract] [Full Text] [Related]
40. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting. Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]